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ABSTRACT
Programmed  1 ribosomal frameshifting ( 1 PRF) is
a mechanism that directs elongating ribosomes to
shift-reading frame by 1 base in the 50 direction that
is utilized by many RNA viruses. Importantly, rates
of  1 PRF are fine-tuned by viruses, including
Retroviruses, Coronaviruses, Flavivriuses and in two
endogenous viruses of the yeast Saccharomyces
cerevisiae, to deliver the correct ratios of different
viral proteins for efficient replication. Thus,  1 PRF
presents a novel target for antiviral therapeutics.
The underlying molecular mechanism of  1 PRF is
conserved from yeast to mammals, enabling yeast
to be used as a logical platform for high-throughput
screens. Our understanding of the strengths and
pitfalls of assays to monitor  1 PRF have evolved
since the initial discovery of  1 PRF. These include
controlling for the effects of drugs on protein ex-
pression and mRNA stability, as well as minimizing
costs and the requirement for multiple processing
steps. Here we describe the development of an
automated yeast-based dual fluorescence assay
of  1 PRF that provides a rapid, inexpensive auto-
mated pipeline to screen for compounds that alter
rates of  1 PRF which will help to pave the way
toward the discovery and development of novel
antiviral therapeutics.
INTRODUCTION
Programmed  1 ribosomal frameshifting ( 1 PRF) is a
mechanism by which cis-acting elements in an mRNA can
direct elongating ribosomes to shift reading frame by 1
base in the 50 direction (1–3). Many RNA viruses utilize
 1 PRF, including most Retroviruses, Coronaviruses,
Flaviviruses and Totiviruses. In Retroviruses and
Totiviruses, the open reading frame (ORF) encoding the
major viral nucleocapsid proteins (e.g. Gag) is located at
the 50-end of the mRNA whereas the ORFs encoding
proteins with enzymatic functions (typically Pro and
Pol) are located 30 of, and out of frame with, the Gag
ORF. The mRNAs transcribed from these viral templates
contain two overlapping ORFs. The enzymatic proteins
are only translated as a result of a programmed ribosomal
frameshift event that occurs with an efﬁciency of 1–40%
depending on the speciﬁc virus and assay system employed
(4). Thus, the majority of translational events result in the
production of the Gag protein, while a minority of frame-
shifts yield viral enzymatic proteins. The ratio of Gag
to Gag-pol synthesized in viruses as a consequence of pro-
grammed frameshifting varies between a narrow window
of 20:1 to 60:1 (2). In Coronaviruses and Flaviviruses,
frameshift events occur over a wider dynamic range to
regulate the relative ratios of non-structural proteins (5–7).
The importance of maintaining precise ratios of viral
proteins on virus propagation has been demonstrated in
Retroviruses, Coronaviruses, Flavivriuses and in two en-
dogenous viruses of the yeast Saccharomyces cerevisiae
(5–8). Starting with the yeast ‘killer’ virus, we have exten-
sively documented that small alterations in programmed
frameshifting efﬁciencies promote rapid loss of the yeast
dsRNA L-A ‘killer’ virus (9–20). In L-A, Gag-pol dimer-
ization nucleates formation of the virus particle (21–24).
Increasing the amount of Gag-pol protein synthesized may
cause too many particles to initiate non-productively while
producing too little may prevent efﬁcient dimerization (9).
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ribosomal frameshift in the Ty1 retrotransposable element
of yeast results in reduced retrotransposition frequencies
(11,17,25–30). Proteolytic processing of the TyA-TyB
(Gag-pol equivalent) polyprotein of Ty1 is analogous to
Gag-pol processing in retroviruses. In Ty1, increasing the
amount of Gag-pol protein synthesized inhibited proteo-
lytic processing of the polyprotein (25). As a consequence,
formation of the mature forms of RNase H, integrase and
reverse transcriptase is blocked (25). Similarly, changing
the ratio of Gag to Gag-pol proteins in retroviruses like
HIV or Moloney Murine Leukemia Virus interferes with
virus-particle formation (31–36). In these cases, over-
expression of the Gag-pol protein results in inefﬁcient pro-
cessing of the polyprotein and inhibition of virus produc-
tion. Although the products produced by  1 PRF are
different in Coronaviruses and Flaviviruses, the conse-
quences of changes in  1 PRF efﬁciency are similar: in
Coronaviruses, small changes in  1 PRF negatively
impact on production of infectious virus (7), while in the
Japanese encephalitis ﬂavivirus, changes in  1 PRF are
important for neuroinvasiveness (5). In sum, viral PRF
efﬁciencies have been ﬁnely tuned to deliver the precise
ratios of proteins required for efﬁcient viral particle
assembly: too much or too little frameshifting alters this
ratio, with detrimental consequences.
Based on these studies, it has been proposed that  1
PRF presents a novel target for prevention of viral propa-
gation (8). To this end, development of simple, cost effect-
ive assay systems would hasten identiﬁcation of
therapeutic agents that target this molecular mechanism.
A number of quantitative assays have been employed to
monitor  1 PRF. Cell free in vitro translation assays have
the advantage of directly monitoring product formation,
providing accurate readouts of the amounts and molecular
weights of frameshift products. However, direct product
monitoring presents numerous roadblocks to high-
throughput screening (HTS) applications including the re-
quirement for in vitro translation systems and radioactive
labeling, the relatively small amount of products and
the requirement for multiple secondary processing steps
including SDS-PAGE, autoradiography, and/or immuno-
precipitation. Mass spectrophotometric methods, while
highly accurate, are also problematic for the same
reasons. Enzymatic assays have been the preferred route,
as they can be performed in either live cells or cell extracts,
they do not require direct monitoring of the frameshift
products, and they do not require use of radioactive
materials or extensive handling. The ﬁrst such assays em-
ploying monocistronic reporter systems were confounded
by effects on reporter mRNA stability, producing false
positive results; this was corrected by development of
dual-reporter constructs which internally control for
effects on mRNA stability and differences in rates of tran-
scription (37–39). These second generation systems utilize
lacZ and/or luciferases as reporter enzymes, which poses
two drawbacks with regard to their utility in high-
throughput screens: they require numerous manipulation
steps, and they are not cost-effective. More recently, a
mammalian cell in vivo dual-ﬂuorescent protein-based
system was described that enables rapid and accurate
screening of compounds without the requirement for
labor-intensive manipulations and expensive reagents
(40). However the costs associated with producing and
maintaining reporter cells using this system remain pro-
hibitive. Here, we describe the development of a yeast-
based dual-ﬂuorescence system that can accurately detect
even very slight changes in  1 PRF caused by mutations
and drugs. This single plate assay is rapid, inexpensive and
amenable to HTS applications.
MATERIALS AND METHODS
Yeast strains and plasmids
JD932 (MATa ade 2-1 trp1-1 ura3-1 leu2-3, 112 his3-11, 15
can1-100) was used for anisomycin studies. The wild-type
L11 yeast strain was JD1381 (MAT  ura3-52 leu2D1
trp1D63 his3D200 rpl11a::HIS3 rpl11b::HIS3+
YCpRPL11B-TRP1). Isogenic rpl11 mutant strains were
based on JD1381, but contained low copy TRP1-CEN6-
based plasmids expressing mutant versions of ribosomal
protein L11. These were: JD1382 (rpl11-Y52 ), and
JD1433 (rpl11-92-6A). All dual ﬂuorescence plasmids
used in this study were based on pRS426 (41), a high
copy 2m, URA3 vector. Transcription was directed from
a yeast G6PD promoter into the monomeric Ds-Red ORF
followed by the EGFP ORF reporter mRNAs. In
pJD0980, the Ds-Red ORF was followed by the yeast
L-A virus derived  1 PRF signal, which was in turn
followed by the EGFP ORF, which was in the  1
reading frame relative to Ds-Red, so that synthesis of
EGFP protein was contingent upon a  1 PRF event.
pJD0981 was the same as pJD0980 except that one nu-
cleotide was inserted immediately 50 of the L-A  1 PRF
signal, inactivating the  1 PRF signal and placing the
EGFP ORF in the same frame as Ds-Red: this was used
as the 0-frame control). Similarly, pJD1197 harbored the
HIV-1 M type -1 PRF signal with EGFP in the  1 frame,
while and pJD1198 was used as the HIV-1 M type 0-frame
control. pJD0395 (a.k.a. pRS426) was used as the empty
vector control.
Dual ﬂuorescence assay
Yeast cells were transformed with empty vector plasmid
(vector without ﬂuorescence protein-coding sequences or
frameshifting signal), control reporter plasmid (0-frame)
and test reporter plasmid ( 1 frame). Transformants were
selected for on H-Ura plates for 3 days at 30 C. Colonies
were transferred to 2ml of liquid H-Ura medium and
grown overnight in a 30 C shaker. Cultures were diluted
50-fold in H-Ura medium with or without 60mg/ml
anisomycin, mixed and aliquots of 150ml were placed in
96-well plates. In the assays presented here, each reporter
was represented by six replicates per plate per strain. The
outer wells of each plate did not contain samples, but were
ﬁlled instead with 150ml of water to evenly account for
evaporation and condensation rates among sample wells.
Plates were covered with lids, sealed with paraﬁlm and
incubated in a Synergy HT microplate reader at 30 C
for 46h without shaking. Cell density was monitored by
absorbance at 595nm every 20min over a period of 46h.
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530nm) and red (excitation 550nm, emission 640nm)
ﬂuorescence readings were taken.
 1 PRF (FS%) was calculated as follows:
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where G is the green ﬂuorescence for yeast transformed
with test or control vector; Gev is green ﬂuorescence for
yeast transformed with empty vector; R is red ﬂuorescence
for yeast transformed with test or control vector; Rev is red
ﬂuorescence for yeast transformed with empty vector; OD
is the optical density of cells transformed with reporter
plasmid, and ODev is optical density of cells transformed
with empty vector.
Dual luciferase assays
Yeast were transformed with the Renilla-ﬁreﬂy dual
luciferase control and test plasmids: pJD0419 (L-A 0
frame control), pJD420 (L-A  1 PRF tester), pJD0375
(HIV 0 frame control) and pJD0378 (HIV  1 PRF
tester) (39). Yeast were plated onto selective media for
3 days and then transferred to 4ml of selective media
with or without 60mg/ml anisomycin. Cells were incubated
overnight in a 30 C shaker till mid-logarithmic growth at
an OD595 of 0.6–1.5. Yeast were washed three times and
lysed with PBS plus 1mM PMSF using 0.5mm glass
beads and a bead beater followed by centrifugation to
clarify the lysate. Each strain was measured seven times
for each reporter by sequentially mixing 10ml of lysate
with 50ml of Promega’s LARII reagent followed by 50ml
of Stop and Glo dual luciferase reagent, quantifying each
step using a 96-well plate-reading Turner BioSystems
Modulus microplate luminometer. Assays of  1 PRF
and statistical analyses were performed as previously
described (42).
RESULTS
A simple and inexpensive assay of  1 PRF in yeast
While the dual luciferase reporters are excellent for moni-
toring  1 PRF in small numbers of samples, there are
three reasons why it is not particularly amenable for
HTS applications. The ﬁrst is cost: each sample costs ap-
proximately $2 ($1 each for test and control). Second, it is
labor and time intensive: cells have to be lysed and cleared,
lysates have to be spectrophotometrically read and nor-
malized for protein content and two sets of reagents have
to be sequentially introduced into lysates and read. With
these limitations in mind, we developed a dual-ﬂuorescent
 1 PRF assay system for use in live yeast cells. A control
reporter, in which monomeric Ds-Red and EGFP are in
frame, provides baseline data (Figure 1A). In the frame-
shift reporter plasmid, EGFP production is dependent on
 1 PRF, while Ds-Red serves as the internal control
(Figure 1B). Figure 1C shows that high levels of Ds-Red
and EGFP can be expressed using these vectors.
Figure 2A shows a timecourse experiment monitoring
HIV-1 promoted  1 PRF monitored every 20min for a
total of 46h in the presence (pink traces) or absence (blue
traces) of 60mg/ml anisomycin, a drug that inhibits  1
PRF (13). Note that the signals were extremely noisy
during the ﬁrst  12h. This is likely due to a combination
of two factors: low cell densities and the time-dependent
requirement for the two reporter proteins to mature, es-
pecially in the low-oxygen environment of this assay. As
the proteins matured and densities increased, frameshift
efﬁciencies began to become discernable, tending to stabil-
ize at  30h. At the 46-h endpoint, HIV-1 promoted  1
PRF efﬁciency in untreated cells leveled off at  13%, a
value that is comparable to  1 PRF measured using the
dual luciferase reporter in yeast cells (39). Notably, this
assay was also able to recapitulate the inhibitory effect of
anisomycin, which promoted  8%  1 PRF at the 46-h
timepoint. Figure 2B shows a plot of the effects of ani-
somycin on  1 PRF as fold wild-type levels,
demonstrating that this drug inhibits  1 PRF by  40%,
consistent with previous ﬁndings (13).
Next, we tested the ability of this system to identify
changes in  1 PRF encoded by the yeast L-A virus  1
PRF signal due to either the presence of 60mg/ml
anisomycin or consequent to cellular mutations known
to affect  1 PRF. Speciﬁcally, anisomycin and the yeast
rpl11-92-96A mutant were expected to promote decreased
rates of  1 PRF, while the rpl11-Y52  mutant was ex-
pected to promote increased  1 PRF (43, M.H.J. Rhodin
and J.D. Dinman, unpublished data). Figure 3A shows a
PRF signal
Ds-Red GFP (0-frame)
Reporter gene
Protein
Reporter gene
Proteins
Control Plasmid
Test Plasmid
A
B
Ds-Red EGFP Bright Field C
+1 nt
GFP (-1 frame) Ds-Red
PRF signal
Figure 1. Dual-ﬂuorescence reporter system. (A) Read-through control
plasmid contains Ds-Red and EGFP ORFs. Note that insertion of one
nucleotide 50 of the  1 PRF signal inactivates frameshifting, and places
the EGFP ORF in frame with the Ds-Red ORF to produce the
Ds-Red/EGFP fusion protein. (B)  1 PRF test plasmid is the same
as the control plasmid except that the EGFP ORF is in the  1 frame
with respect to the Ds-Red ORF. No frameshift results in production
of Ds-Red only, while a frameshift event results in production of the
Ds-Red/EGFP fusion protein. (C) Microscopic images of cells trans-
formed with the control plasmid.
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for 46h. Again, the system was noisy for the ﬁrst  12h
and began to stabilize at  30h. Taking 46h as the end-
point, Figure 3B shows that the system produced the ex-
pected results. Speciﬁcally, anisomycin inhibited both
HIV-1 (data duplicated from Figure 2B) and L-A-
mediated  1 PRF. Further, L-A-mediated  1 PRF was
decreased in the rpl11-92-96A mutant, and it was
increased in the rpl11-Y52  strain.
The dual-ﬂuorescent reporter system recapitulates data
obtained using a dual-luciferase reporter system
The experiments were repeated using our previously desc-
ribed dual luciferase assay system (39) to compare the re-
sults obtained using the dual ﬂuorescent reporter system.
Side by side comparisons shown in Figure 3B demonstrate
strong agreement between the two assay systems. These
results match our previous ﬁndings for these conditions
where 60mg/ml anisomycin inhibited  1 PRF, rpl11-
Y52  promoted increased  1 PRF and rpl11-92-6A
promoted decreased  1 PRF. This independent validation
underscores the potential for the less expensive and scal-
able dual ﬂuorescence methodology to accurately detect
changes in frameshifting.
DISCUSSION
The ﬁndings described here demonstrate the production of
a robust and inexpensive assay that faithfully reproduces
changes in  1 PRF due to cellular mutations and addition
of drugs. An advantage to using the multiple well format
is that it enables the data collected by the reader to be dir-
ectly transferred into an excel spreadsheet, where  1 PRF
rates are automatically calculated (42). Importantly, this
software also determines standard errors, and ﬂags
samples with statistically signiﬁcant Z-scores, rendering
it ideal for HTS applications. Features inherent in the cal-
culation of  1 PRF efﬁciency using the yeast-based in vivo
dual-ﬂuorescence assay also have two critical built in ad-
vantages with respect to counter screening. First, since the
assay requires normalization of cell density by measuring
OD595, this parameter can be used to monitor the effects
of compounds on cell growth, that is, to ﬂag potential cell
toxicity. Second, since it requires normalization to an
in-frame control, these measurements can be used to
identify deleterious effects on overall protein synthesis.
While we have only monitored  1 PRF from the L-A
and HIV-1 frameshift signals, the modular nature of the
reporter vectors renders insertion of  1 PRF signals from
other human pathogenic viruses e.g. HTLV-I (Retrovirus
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Figure 3. Effects of anisomycin and host cell mutants on HIV-1 and
L-A promoted  1 PRF. (A) Time course assay. Wild-type cells
harboring either HIV-1 or L-A  1 PRF reporters were treated with
60mg/ml anisomycin. In parallel, isogenic rpl11 mutant strains were
assayed using the L-A  1 PRF reporter. Data are normalized to
no-drug or isogenic wild-type RPL11 cells. (B) Comparison of data
obtained using dual ﬂuorescence or dual luciferase reporters. Solid
colored bars indicate 46-h endpoint measurements of  1 PRF ex-
pressed as fold wild-type or untreated cells. Striped bars represent
fold wild-type results using dual luciferase reporter system for same
cell types and testing conditions. Error bars indicate standard error.
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Figure 2. (A) Time course assay of HIV-1-promoted  1 PRF in yeast
cells in the presence or absence of 60mg/ml anisomycin. Error bars
indicate standard error. (B) The effect of 60mg/ml anisomycin on
HIV-1  1 PRF determined as fold untreated cells.
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Forest virus (Alphavirus family) and the NS2A-coding
sequences of Flaviruses such as Japanese encephalitis
virus, Eastern equine encephalitis virus and West Nile
virus quite simple. As we and others have empirically
determined that even very small changes in  1 PRF
have strongly deleterious effects on virus propagation
[reviewed in (8)], we suggest that initial cut-offs be set at
>1.2-fold and <0.8-fold of wild type. These liberal cut-off
values allow for a higher rate of false positives rather than
false negatives, thus allowing false positives to be identi-
ﬁed later with secondary assays. In addition, this basic
format should be amenable for assays of other transla-
tional recoding mechanisms, for example, +1 PRF and
termination codon suppression.
Once candidates are identiﬁed using this platform, sec-
ondary assays will be required to validate hits. Here we
suggest two such assays. (i) Maintenance of the yeast
‘killer’ virus. We have shown that maintenance of this
virus is critically dependent on  1 PRF, and have exten-
sively used this property to validate changes in  1 PRF
due to cellular mutations and drugs (8,44). Importantly,
this assay provides an independent means to screen for
antiviral effects of compounds that can be correlated
with effects due to changes in  1 PRF. The killer assay
involves replica-plating test cells onto a lawn of uninfected
indicator yeast cells seeded onto 4.7 MB plates (yeast rich
medium containing 0.5% methylene blue, pH 4.7). Cells
are grown at 20 C for 4 days, and then visually inspected
for the presence of a zone of growth inhibition due to pro-
duction of the virus-encoded killer toxin. These assays are
very simple and inexpensive, requiring only yeast cells,
media and petri dishes. Currently, the dual ﬂuorescence
assay can screen up to 20 samples per 96-well plate if
forgoing multiple replicates. Assuming initial identiﬁca-
tion of 500 compounds, these assays could be performed
on as few as 25 plates when controls are included. The
killer assay can be either performed manually (in the
case of a few hits), or can be scaled up for high-throughput
robotic screening. We believe that robotic technology cur-
rently used for high-throughput yeast 2-hybrid screens can
be adapted to the killer assay. A potential disadvantage of
this assay is that it may require serial passage of yeast cells
to multiple rounds of drug exposure. For example, we
have found that curing of killer by anisomycin requires
at least two serial passages in the presence of this drug.
Loss of the killer virus is further validated by extracting
total RNA from cells, followed by non-denaturing 1.2%
agarose gel electrophoresis, which detects the presence or
absence of the viral dsRNA genome. (ii) Dual luciferase
assays. In order to validate potential hits,  1 PRF values
can be determined using both in vivo (live yeast cells and in
HeLa cells), in vitro (rabbit reticulocyte lysates) dual-
luciferase assays as previously described (39,45). These
can be used to conﬁrm the  1 PRF data obtained using
dual-ﬂuorescence reporters. The dual-luminescence assay
as a secondary assay is also advantageous in that it
enables identiﬁcation of compounds that truly affect  1
PRF, as opposed to those that affect production or activity
of the Ds-Red or EGFP reporter proteins. A further
advantage of the in vitro assay is that it can identify
compounds that directly affect  1 PRF as opposed to
compounds that affect transcription of the reporter
mRNAs.
There are a number of parameters that remain to be
reﬁned. One is automation, speciﬁcally plate seeding. In
an industrial setting, this can easily be addressed using a
robotic pipettor. Robotic pipetting can also solve the
problem of interference of OD and ﬂuorescence readings
due to the presence of condensation on the plate lid at the
end of the incubation period. Robotic transfer of cells to
new plates just prior to reading will solve this problem.
Data integrity is another problem that can be addressed
by automation coupled with plate bar-coding, which will
also assure that the worklist downloaded to the robot has
100% integrity. The data also have to be organized into a
query-able format. However, the software that we de-
veloped to ﬂag statistically signiﬁcant Z-scores address
this issue, and can also address the issue of operator
bias. Process bottlenecks are also a common problem
with HTS. In this case, the major bottleneck is the time
required for maturation of the reporter proteins, hence the
decision to take the 46h endpoint. However, growth con-
ditions may be further optimizable by incubating in a
more humid and oxygenated environment, potentially
reducing the time required for signal stabilization.
Additionally, parallel processing of multiple plates can
speed this process, rendering this bottleneck insigniﬁcant.
For HTS, each plate must contain internal controls. We
suggest that rpl11-Y52  mutant cells and rpl11-92-6A
mutant cells or a sample containing anisomycin can be
used as quality control for up- and down-frameshifting,
respectively. Pooling is also commonly used in HTS.
Although the idea is attractive, our experience is that
this leads to mistakes, and we would recommend against
this approach. Cell wall permeability is a common issue
associated with yeast-based HTS because yeast cell walls
are impermeable to many small molecules. However, yeast
cells easily tolerate DMSO to concentrations of up to
0.8%. Thus, this reagent could be used to rectify this po-
tential problem. Finally, most HTS technologies utilize
384 or 1536 well plates, and thus there are questions
about ability to scale up this assay. However, there is a
priori no reason for why scaling up to more wells will not
work, although it is possible that scaling-up to higher
density formats may present issues with oxygen transfer
needed to support cell growth for this in vivo assay.
Assuming this oxygen limitation is a problem, the incuba-
tor could easily be designed to increase the ambient
oxygen content, thus mitigating any such problem.
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